Obesity and Weight Loss Strategies for Patients With Heart Failure
Document Type
Article
Publication Date
7-31-2024
Publication Title
JACC: Heart Failure
Abstract
Obesity is a common comorbidity among patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), with the strongest pathophysiologic link of obesity being seen for HFpEF. Lifestyle measures are the cornerstone of weight loss management, but sustainability is a challenge, and there are limited efficacy data in the heart failure (HF) population. Bariatric surgery has moderate efficacy and safety data for patients with preoperative HF or left ventricular dysfunction and has been associated with reductions in HF hospitalizations and medium-term mortality. Antiobesity medications historically carried concerns for cardiovascular adverse effects, but the safety and weight loss efficacy seen in general population trials of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide/GLP-1 agonists are highly encouraging. Although there are safety concerns regarding GLP-1 agonists in advanced HFrEF, trials of the GLP-1 agonist semaglutide for treatment of obesity have confirmed safety and efficacy in patients with HFpEF.
First Page
1509
Last Page
1527
PubMed ID
39093256
Volume
12
Issue
9
Recommended Citation
Vest, Amanda R.; Schauer, Philip R.; Rodgers, Jo E.; Sanderson, Emily; LaChute, Courtney L.; Seltz, Jessica; Lavie, Carl J.; Mandras, Stacy A.; Tang, W. H. Wilson; and daSilva-deAbreu, Adrian, "Obesity and Weight Loss Strategies for Patients With Heart Failure" (2024). School of Medicine Faculty Publications. 3552.
https://digitalscholar.lsuhsc.edu/som_facpubs/3552
10.1016/j.jchf.2024.06.006